: July 23, 2024
Horsham, PA - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leading medical technology company specializing in innovative dermatologic treatments, has recently completed a registered direct offering to raise $2.1 million. The offering, priced at-the-market under Nasdaq rules, saw the issuance and sale of 665,136 shares of common stock at an average purchase price of $3.16 per share.
This is an important development for STRATA as it seeks to navigate the challenging landscape of dermatological conditions. The funds raised in this offering will be used to support the company’s ongoing efforts in developing, commercializing, and marketing its innovative products for the treatment of various skin ailments.
The registered direct offering was executed in compliance with a shelf registration statement (Form S-3, Registration No. 333-258814) previously filed by the company with the Securities and Exchange Commission (SEC) on August 13, 2021. The statement, which was declared effective by the SEC on October 15, 2021, and subsequently amended on June 24, 2024, allowed STRATA to offer and sell its common stock to interested investors.
Of noteworthy significance is the participation of insiders and previously existing shareholders in the completed direct offering. Their involvement underscores their faith in STRATA’s future prospects despite its recent financial performance.
It is worth mentioning that STRATA Skin Sciences Inc recorded a cumulative net loss of $-11 million during the 12 months ending in the first quarter of 2024. This resulted in a negative return on investment (ROI) of -34.03%. However, the company’s ability to attract the financial support of insiders and existing shareholders indicates their belief in the potential of STRATA’s products and their confidence in the management team.
The dermatology market is highly competitive, and STRATA Skin Sciences faces challenges in gaining market share and profitability. However, the completion of this direct offering provides the company with additional capital to execute its growth strategy and expand its customer base.
STRATA must now focus on optimizing its operations and diligently bringing its innovative dermatologic treatments to market. With the support of insiders and shareholders, the company can navigate the complexities of the industry and potentially realize future success.
Comments